13:27 Fri 13 Oct 2017
The FDA will decide on Aerie’s Rhopressa eye drop this morning
Aerie Pharmaceuticals Inc (NASDAQ:AERI) is in the spotlight on Friday as the US Food and Drugs Administration is set to judge an application for its new eye drug.
Trading in the stock is on hold this morning as the FDA’s dermatologic and opthalmic drugs advisory committee will meet to review Aerie’s Rhopressa eye drop.
Rhopressa is intended to be a once daily application designed to reduce pressure on eyes resulting from glaucoma.
Price: 11.21 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
HANetf and GinsGlobal Index Funds' Managing Director Anthony Ginsberg joined Steve Darling from Proactive to share details about the success of their Healthcare Innovations ETF. Ginsberg discusses how COVID-19 had made a direct impact on that fund, especially in the telemedicine...
Retail & consumer
